News

04 April, 2018

Zelluna Immunotherapy appoints Arjan Roozen as Chief Technology Officer

Oslo, Norway, April 16, 2018 - Zelluna Immunotherapy, the biotechnology company specializing in T-cell receptor (TCR) immunotherapies targeting a broad range of solid cancers with a high unmet medical need, today announces the appointment of Arjan Roozen as chief technology officer (CTO).

“Zelluna appointed Arjan specifically for his wide-ranging knowledge in key areas of cell therapy product manufacturing,” said Miguel Forte, CEO, Zelluna. “Arjan’s experience, acquired on both sides of the Atlantic, will prove invaluable for Zelluna in its immediate focus of delivering clinical proof of concept of its TCRs in adoptive cell therapy for solid cancers. He will play a big part in the execution of Zelluna’s manufacturing strategy for clinical trials and commercialization.”

Arjan was selected by Zelluna as CTO for his experience acquired at Cellectis, the French cell therapy company, where he headed up the GMP solutions and manufacturing team of its gene modified cell therapy. Additionally, he has invaluable experience from the CDMO Pharmacell, recently acquired by Lonza, where he was responsible for all operational activities. Arjan has a degree in microbiology with specialization in molecular microbiology.

Zelluna has also appointed Julia Ino as head of project management. Her experience includes work as product manager, business development and IP manager at Bone Therapeutics (Belgium), where she was instrumental in drug development and overall strategy to deliver a cell therapy product. Julia received her PhD in regenerative medicine at Inserm/Paris XIII. 

Zelluna core asset is a portfolio of tumor specific T cell receptors (TCRs) obtained from long-term surviving patients from solid cancer relevant peptide-based vaccine trials. Zelluna’s TCRs have been tailored by the human immune system delivering an optimal combination of specificity and affinity with a significant potential for tolerable and effective therapy.

“There is a considerable variety of approaches to immuno-oncology across the industry. However, Zelluna’s approach of using TCRs isolated from long-term survivors from cancer vaccine trials is genuinely unique and innovative. It also has, in my view, considerable potential for multiple therapeutic uses,” said Arjan Roozen, CTO, Zelluna. “This clinical potential for oncology patients is a major reason for my joining Zelluna. I hope to play a major part in Zelluna’s product development in the future.”

About Zelluna Immunotherapy
Zelluna Immunotherapy specializes in immunotherapies targeting a broad range of solid cancers with a high unmet medical need. The company is developing a unique portfolio of non-engineered tumor specific T-cell receptors (TCRs) isolated from long-term surviving patients from cancer vaccine trials. The TCRs combine specificity and affinity to have the potential for a safe and efficient therapy to target a variety of common cancer types. Zelluna has a long-term CRADA with the Department for Cell Therapy at Oslo University Hospital (OUH), providing comprehensive capabilities of TCR development, ranging from lead discovery to clinical translation. For more information, please visit www.zelluna.com.

Contact Information:
Image Box PR
Neil Hunter / Michelle Boxall
Tel +44 (0)20 8943 4685
This email address is being protected from spambots. You need JavaScript enabled to view it. / This email address is being protected from spambots. You need JavaScript enabled to view it.